Paraoxonase-1 is a major determinant of clopidogrel efficacy (Q82951856)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170047 AND SRC:MED&resulttype=core&format=json

18 January 2020

title

Paraoxonase-1 is a major determinant of clopidogrel efficacy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170047 AND SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

Christoph Hirschhäuser

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170047 AND SRC:MED&resulttype=core&format=json

18 January 2020

Hans-Günther Schmalz

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170047 AND SRC:MED&resulttype=core&format=json

18 January 2020

author name string

Heleen J Bouman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170047 AND SRC:MED&resulttype=core&format=json

18 January 2020

Edgar Schömig

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170047 AND SRC:MED&resulttype=core&format=json

18 January 2020

Jochem W van Werkum

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170047 AND SRC:MED&resulttype=core&format=json

18 January 2020

Janna Velder

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170047 AND SRC:MED&resulttype=core&format=json

18 January 2020

Christian M Hackeng

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170047 AND SRC:MED&resulttype=core&format=json

18 January 2020

Christopher Waldmann

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170047 AND SRC:MED&resulttype=core&format=json

18 January 2020

Jurriën M ten Berg

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170047 AND SRC:MED&resulttype=core&format=json

18 January 2020

Dirk Taubert

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170047 AND SRC:MED&resulttype=core&format=json

18 January 2020

publication date

19 December 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170047 AND SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170047 AND SRC:MED&resulttype=core&format=json

18 January 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170047 AND SRC:MED&resulttype=core&format=json

18 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170047 AND SRC:MED&resulttype=core&format=json

18 January 2020

page(s)

110-116

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170047 AND SRC:MED&resulttype=core&format=json

Determinants of variation in human serum paraoxonase activity

18 January 2020

cites work

1 reference

12 December 2020

Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters

1 reference

12 December 2020

Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis.

1 reference

12 December 2020

The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin

1 reference

12 December 2020

Structure and stereochemistry of the active metabolite of clopidogrel

1 reference

12 December 2020

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy

1 reference

12 December 2020

Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel

1 reference

12 December 2020

Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis

1 reference

12 December 2020

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

1 reference

12 December 2020

Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies

1 reference

12 December 2020

Pharmacokinetics of clopidogrel after administration of a high loading dose

1 reference

12 December 2020

Platelet function monitoring in patients with coronary artery disease

1 reference

12 December 2020

On the design of synthetic case-control studies

1 reference

12 December 2020

Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis

1 reference

12 December 2020

Analysis of case-cohort designs

1 reference

12 December 2020

Metabolic oxidative cleavage of thioesters: evidence for the formation of sulfenic acid intermediates in the bioactivation of the antithrombotic prodrugs ticlopidine and clopidogrel

1 reference

12 December 2020

Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes

1 reference

12 December 2020

Investigation of the relationship between atherosclerosis and paraoxonase or homocysteine thiolactonase activity in patients with type 2 diabetes mellitus using a commercially available assay

1 reference

12 December 2020

Genetic Polymorphism of CYP2C19 Gene in the Stanislas Cohort. A link with Inflammation

1 reference

12 December 2020

Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite

1 reference

12 December 2020

Platelet adenosine diphosphate P2Y12 receptor antagonism: benefits and limitations of current treatment strategies and future directions

1 reference

12 December 2020

Recent developments in clopidogrel pharmacology and their relation to clinical outcomes

1 reference

12 December 2020

Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel

1 reference

12 December 2020

Paraoxonase 1 protects against protein N-homocysteinylation in humans

1 reference

12 December 2020

Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes.

1 reference

12 December 2020

Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel

1 reference

12 December 2020

ACCF/AHA Clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association

1 reference

12 December 2020

Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk

1 reference

12 December 2020

Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel

1 reference

12 December 2020

Variability in platelet responsiveness to clopidogrel among 544 individuals.

1 reference

12 December 2020

Genetic determinants of response to clopidogrel and cardiovascular events

1 reference

12 December 2020

2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evide

1 reference

12 December 2020

Identifiers

DOI

10.1038/NM.2281

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170047 AND SRC:MED&resulttype=core&format=json

18 January 2020

1 reference